



**BIONEUTRA GLOBAL CORPORATION
DAVID HANCOCK, Q.C., LL.D (HONS) APPOINTED TO THE ALBERTA
PROVINCIAL COURT**

Edmonton, Alberta – (December 19, 2017) – BioNeutra Global Corporation (“BioNeutra” or the “Company”) (TSXV: BGA) is pleased to announce that David Hancock, Q.C., LL.D (Hons) has been appointed to the Provincial Court of Alberta as a family and youth court judge in the City of Edmonton. As a result of his judicial appointment, Mr. Hancock is required to resign from the Board of Directors with the Company (the “Board”).

Mr. Hancock joined the Company in October of 2015, and contributed to the successful development of the Company. Management and the Board of Directors extend their sincere gratitude to Mr. Hancock for his substantial efforts and dedicated service to BioNeutra over the past years.

Dr. Jianhua Zhu, the Chief Executive Officer and Director of the Company, states; “On behalf of the Board, we wish to congratulate Mr. Hancock on his appointment as a Provincial Court Judge and it is with regret that we accept his resignation. Dave has made many valuable contributions to the Board of BioNeutra and we thank him for his commitment, dedication and assistance to the Company.”

Mr. Bill Smith, Chairman of the Board, and former Mayor of the City of Edmonton, states; “David contributed exceptionally to our Board. His guidance with the Directors and management displayed his insight into business and law. His decisiveness and calming presence will be sorely missed.

Thank you David. I know you will continue to serve Albertans and Canadians and we will all benefit from your experience and dedication.”

Mr. Hancock comments; “It has been a privilege working with the Board of BioNeutra. The Company has an exciting future and I will miss working with you to attain the success you so richly deserve.”

About BioNeutra

BioNeutra is in the business of research and development, production and commercialization of ingredients for nutraceutical, functional and mainstream foods and beverages, with a focus on VitaFiber™ IMOs.

The Company’s lead product, VitaFiber™, is an advanced functional and health food and beverage ingredient scientifically made from natural agricultural products, is generally regarded as safe (GRAS) by the U.S. Food & Drug Administration, and is European Food Safety Authority and Health Canada approved as a novel food ingredient. VitaFiber™ is naturally sweet and lower in calories than regular sugar and is a natural source of dietary fiber as it provides low calorie soluble prebiotic fiber for human digestive health.



The Company produces VitaFiber™ using its patented processes that naturally transform starch molecules from agriculture cereal crops including corn, wheat, barley, potato, or tapioca into the functional health molecules of VitaFiber™ IMO. The VitaFiber™ manufacturing process is based upon a natural enzymatic conversion of starch molecules without any chemical modification involved, making VitaFiber™ a natural food and beverage ingredient. VitaFiber™ is also non-GMO, vegan-friendly, gluten-free, Kosher and Halal certified and available as certified organic.

The Company's customers include a mix of small and medium enterprises and a number of high-profile food and beverage manufacturers in Canada, the U.S., Europe, the United Kingdom, and Mexico. VitaFiber™ is also available for retail purchase across the globe through Amazon.com and other direct-to-consumer retailers.

Further information about BioNeutra is available on the Company's website at www.bioneutra.ca and the SEDAR website at www.sedar.com.

For further information on BioNeutra, please contact:

Mr. Bill Smith
Chairman & Senior Vice President
Tel: (780) 466-1481 (Ext. 117)
Email: bsmith@bioneutra.ca

Forward-Looking Information

This press release may include forward-looking information within the meaning of Canadian securities legislation concerning the business of BioNeutra. Forward-looking information is based on certain key expectations and assumptions made by the management of BioNeutra. Although BioNeutra believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioNeutra can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioNeutra disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or any applicable securities laws or any state of the United States and may not be offered or sold in the United States or to the account or benefit of a person in the United States absent an exemption from the registration requirements.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.